Antagningsseminarium för nya doktorander vid Institutionen för molekylär medicin och kirurgi
Antagningsseminarium för nya doktorander vid Institutionen för molekylär medicin och kirurgi
Transcriptional, epigenetic and lipidomic responses to metabolic interventions in humans - Implications for human obesity
Jan Eriksson, Uppsala Universitet
Rachel Fisher, Karolinska Institutet
Jan Zedenius, Karolinska Institutet
Ola Hansson, Lund Universitet
Welcome to the 7th Stockholm Arthroscopy and Rehabilitation Conference in Stockholm arranged by Stockholm Sports Trauma Research Center (CIFU) together with Capio Artro Clinic.
We have the pleasure to present some international top physicians this year including:
Dr. Augustus D. Mazzocca is a professor in the Department of Orthopaedic Surgery at UConn Health. He is the director of the Orthopaedic Bioskills Laboratory, and director of Resident Education for the Department of Orthopaedic Surgery. He is also an active team physician for the UConn athletic teams. Dr. Mazzocca specializes in the management of shoulder and elbow problems.
Dr. Smith joined Columbia Orthopaedic Group in 1986 and specializes in arthroscopic surgery and sports medicine. He has served as the Head Team Physician for the University of Missouri athletic department since 1991; he recently received the “Sports Medicine Hall of Fame Award” by the Missouri Athletic Trainer’s Association for outstanding service, dedication and contribution in the field of Sports Medicine (June 2010). He is a Clinical Assistant Professor of Surgery at the University of Missouri-Columbia, and most recently (2010), Dr. Smith was appointed Director of the Division of Sports Medicine at the University of Missouri in the Department of Orthopaedic Surgery, as well as co-director of the Sports Medicine Fellowship. Dr. Smith specializes in the management of knee injuries but also shoulder problems.
MBChB (UOFS), Social Studies(Oxford), B.Med Sport Hons. (U.C.T.), FCS (SA) Ortho. President of South African Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine. Dr van der Merwe is recognized as an authority in knee surgery. His extensive experience in knee injuries and surgery has seen him being invited to lecture at many orthopaedic conferences around the world. Areas of specialty and interest are Knee Injuries, Sports Medicine, Arthroscopic Knee surgery for ligament reconstruction and meniscal repair, Minimal Invasive total knee replacements, Minimal Invasive Uni-compartment knee replacement, Computer assisted surgery for knee replacements.
Antagningsseminarium för nya doktorander vid Institutionen för molekylär medicin och kirurgi
Diabetes and bone disease
Bente Langdahl, Aarhus University Hospital
Anna Nilsson, Sahlgrenska Universitetssjukhuset
Lisa Juntti-Berggren, Karolinska Institutet
Per Kristiansson, Uppsala Universitet
In vitro and in vivo studies of apolipoprotein CIII in diabetes
Peter Bergsten, Uppsala Universitet
Rachel Fischer, Karolinska Institutet
Gun Jörneskog, Karolinska Institutet
Tore Bengtsson, Stockholms Universitet
Antagningsseminarium för nya doktorander vid Institutionen för molekylär medicin och kirurgi
Improved surgical therapy for oesophageal cancer
Huvudhandledare: Jesper Lagergren
Evaluation of anti-diabetic activity of Bolivian potentially nutraceutical plants
Huvudhandledare: Claes-Göran Östenson
Studies of SNAP-25 in regulated membrane fusion; metabolic consequences and tuning of intracellular Ca2+ dynamics in beta cells
Anders Tengholm, Uppsala Universitet
Christian Broberger, Karolinska Institutet
Per-Ola Carlsson, Uppsala Universitet
Ingrid Dahlman, Karolinska Institutet
Quality of life in patients with thyroid cancer
Camilla Schalin-Jäntti, Helsingfors Universitet
Lena Wettergren, Karolinska Institutet
Göran Wallin, Örebro Universitet
Stig Valdemarsson, Lunds Universitet
Antagningsseminarium för nya doktorander vid Institutionen för molekylär medicin och kirurgi
"Novel Approaches for Treating and Understanding Aortic Valve Disease"
Förhandsgranskare: Daniel Nilsson, Richard Rosenquist, Joonas Kauppila, Hannah Adam, Florian Schober
"Anterior cruciate ligament injuries - revision surgery and graft failure"
Förhandsgranskare: Paul Ackermann, Jan van der Linden, Maria Westin, Robin Fröbom, Maria Pettersson
"Epidemiological Studies of Bioprosthetic Aortic Valves"
Förhandsgranskare: Lennart Blomquist, Anna Lindstrand, Ivan Shabo, Meike Paschen, Cheng Xu
Professor Richard Rosenquist Brandell, was recently appointed Professor of Clinical Genetics at the Department of Molecular Medicine and Surgery, Karolinska Institutet and Senior Physician in Clinical Genetics at Karolinska University Hospital.
He will talk about his group’s experience in applying next-generation sequencing technologies to decipher the genomic landscape of chronic lymphocytic leukemia and outline his future research plans at KI.
Title: "Charting the genomic landscape in chronic lymphocytic leukemia"
Reference paper for further reading: Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. Blood. 2016
Coffee and sandwich is served at 11.30. After the seminar, there is time for discussions. No registration is needed.
Locally recurrent rectal cancer in Sweden-aspects of management, surgery and outcome
Professor Emmanuel Tiret, Universités-Practicien Hospitalier, Paris
Professor Magnus Nilsson, Karolinska Institutet
Professor Maria Albertsson, Syddansk Universitetet
Professor Eva Haglind, Göteborgs Universitet
Genetic causes and molecular mechanisms underlying metabolic diseases
Huvudhandledare: Outimaija Mäkitie
Lecturer: Professor Bente L Langdahl, MD, PhD, DMSc, Aarhus University Hospital, Department of Endocrinology and Internal Medicine, Denmark
Osteoporosis is a common condition that affects many patients, the prevalence increases with increasing age. The treatment of osteoporosis comprises antiresportive and bone forming drugs. The most frequently used antiresorptive treatments comprise bisphosphonates and denosumab. The only bone forming drug available in Europe is teriparatide. None of these treatments have been tested in placebo controlled trial with a placebo comparator for more than 2-3 years, yet our patients need life-long management of their condition.
The long-term management starts with and initial plan for treatment. Important considerations include the severity of the disease, co-morbidities and patient preferences. The initial choice of treatment should be monitored. This will include compliance and response to treatment, measured as changes in bone turnover markers and/or BMD. Fracture during active treatment is always a concern – especially for the patient and treatment failure should be considered.
If the initial treatment choice is teriparatide, this should after end of treatment (1.5-2 years) be followed by treatment with a strong antiresorptive to secure and further mature the bone formed during teriparatide treatment.
If the initial treatment choice was denosumab, the treatment should be continued. There are case reports suggesting an increased risk of vertebral fractures when stopping denosumab. A transfer to bisphosphonate has been suggested as a way of diminishing this risk, however, the optimal timing of starting bisphosphonate is still unknown and investigations are ongoing.
If the initial treatment choice was alendronate or zoledronic acid, a treatment break can be considered after 5 or 3 years, respectively. It is only recommended to consider treatment breaks if the patient never had suffered a vertebral fracture, had not suffered any fracture during the treatment period and has a BMD T-score at the hip above -2.5. The best follow-up strategy during treatment break is not clear; biochemical markers of bone turnover and/or BMD.
New bone forming treatments are underway; abaloparatide and romosozumab that may increase the possibility of treating patients to a treatment goal, for example a hip BMD above -1.5 or -2, a level that has been shown to be associated with a very low risk of non-vertebral fractures.
Professor Kerstin Brismar
Uppstartsmöte för Genomic Medicine Sweden (GMS) en ny nationell infrastruktur för precisionsmedicin
Svenska kliniker, diagnostiker och tekniker över hela landet
Deadline för anmälan har passerat men om du önskar delta så maila till Michael Akhras
Läs mer om projektet på https://www.vinnova.se/p/genomic-medicine-sweden/
Epidemiological and experimental studies on sarcoma with focus on GIST
Huvudhandledare: Robert Bränström
Dagen vänder sig i första hand till patienter med aortasjukdom, anhöriga och personal som möter denna patientgrupp, men alla som är intresserade av dessa sjukdomar är välkomna.
Program och hålltider för Aortadagen
Anmälan görs till Ulrika Lilja Demirovic, på e-mail ulrika.lilja-demirovic@sll.se senast den 13 oktober. Kunskapsdagen är kostnadsfri och öppen för alla som fått bekräftelse på sin föranmälan.
Rebecka Hultgren, Johnny Steuer, Timo Söderlund och Göran Hassel